NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…
2014 ACR/ARHP Annual Meeting: Autoimmune Connective Tissue Diseases and Cancer
Links between autoimmunity, malignancy prompt rheumatologists to include cancer screening for patients
When Rheumatology and Cancer Collide
Chronic inflammation, cancer and autoimmunity are inextricably linked
How Wars Have Shaped Rheumatology
Treating sick, injured soldiers has taught physicians lessons about fighting infections, cancer
Can Scleroderma Be Cured by Curing Cancer?
Research review
How Microbes, Mycobacteria, and Metastases May Alter the Way We Look at Rheumatic Diseases
Studying the relationships between microbes and their hosts, the role for Bacille Calmette Guerin (BCG) as a vaccine for Type I diabetes, and emotional stress and bone metastases
Coding Corner: February’s Coding Challenge
A 62-year-old male patient returns to the office for a followup visit for his gout.
Coding Corner Answer: February’s Coding Challenge
A 62-year-old male patient returns to the office for a followup visit for his gout.
Rheum with a View
Panush’s perspectives on selections from the literature
Are We Playing It Safe?
Tumor necrosis factor alpha inhibition and the risk of solid malignancies
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »